Nov 8 (Reuters) - Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period since the administration of the drug in a late-stage trial. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
985 USD | +0.45% | +0.28% | +12.15% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.15% | 106B | |
+12.30% | 118B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B | |
-2.52% | 7.53B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Regeneron's antibody therapy shows long-term protection against COVID-19